Ruminations of a Taco-Obsessed Philly Native

When Clay Siegall, current CEO of Seattle Genetics, was still in college, one of his family members fell ill with cancer. At that time, the future CEO had no idea what he wanted to do with his life. But when his family member suddenly developed severe anemia as a consequence of taking a large amount of chemotherapy and nearly died from it, Dr. Siegall decided right then and there that he wanted to go into cancer research. If somebody could nearly die from taking the supposed cure for a disease, Dr. Siegall reasoned, there must be a better way to treat it.

After receiving an MS from the University of Maryland in biology and a PhD in genetics from George Washington University, Dr. Clay Siegall was recruited by the National Cancer Institute, one of the most prestigious research institutions in the world. Over the course of the next four years, Dr. Siegall was introduced to a new form of cancer drugs known as targeted cancer therapies. These therapies promised to dramatically reduce the side effects caused by traditional chemotherapeutic regimens due to the ability of these new drugs to specifically target the malignant tissues, avoiding the systemic release of large amounts of poison into the bloodstream.

Over the course of four years, Dr. Siegall proved himself to be an able researcher. He was eventually hired by Bristol-Myers Squibb, one of the largest pharmaceutical companies in the world. There, he worked on a number of projects. One of these was his own pet project, a form of targeted cancer therapy known as antibody drug conjugates. The idea behind antibody drug conjugates was to use the power of the human antibody to seek out malignant tissue directly, only then releasing the highly lethal cytotoxic agent onto the surface of the tumor. In theory, this could completely eliminate the systemic release of highly lethal cytotoxins into the bloodstream, thereby all but eliminating side effects associated with chemotherapy.

Over the course of the next seven years, Dr. Siegall developed this new and innovative form of modified chemotherapy. One of his greatest accomplishments was the development of a novel method by which synthetic antibodies can be produced from rodent antibody templates. Dr. Siegall was able to use live mice to create the molecular template for synthetic human antibodies.

UPDATE — Octoer 17th, 2016 — Seattle Genetics makes good on their word to hire 100 more employees :


Seattle Genetics is a biotechnology company that are leaders in the study of antibody drugs to treat cancer. The company was started in 1998 in Bothell, Washington by Clay Siegall. Bothell, Washington is a suburb of Seattle. The company employs some five hundred to one thousand employees.

The technology at Seattle Genetics takes monoclonal antibodies to kill cancerous cells. Their leading study is the ADCETRIS. The ADCETRIS is the first of the ADCs tests. ADC stands for antibody drug conjugates.

Clay Siegall is the present president and the founder of Seattle Genetics. He studied at the University of Maryland to earn a Bachelor of Science, Zoology degree. He was alumnus of the year in computer, math and science at University of Maryland. Clay Siegall went on to The George Washington University to earn a Ph. D in Genetics. Pacific Northwest Ernst and Young voted him entrepreneur of the year in 2012.

Clay Siegall is additionally the director of many biotechnology companies. He is the director of Alder Biopharmaceuticals, Mirna Therapeutics and Ultragenyx Pharmaceutical.

Dr. Clay Siegall started Seattle Genetics because he has always focused on treating cancer. The purpose of Seattle Genetics is to develops ADCs to treat all types of cancers. With Dr. Clay Siegall leading the company, Seattle Genetics has made over three hundred million dollars. The company has additionally secured more licenses for their ADCs technology under Dr. Siegall’s leadership. Seattle Genetics now have licenses with Genentech, AbbVie, GlaxoSmithKline and Plitzer, which help to improve the ADCs cancer fighting technology.

Seattle Genetics is a biotechnology firm that produces and commercializes innovative antibody therapies for the treatment of cancer and related diseases. The company is an industry leader in antibody-drug conjugates, an innovation aimed at harnessing the targeting abilities of monoclonal antibodies by connecting them with cell-killing agents. The firm has three platform technologies: antibody-drug conjugates (ADCs), antibody-directed enzyme prodrug therapy (ADEPT) and engineered monoclonal antibodies.

Seattle Genetics has created an assortment of products that are targeted to several types of human cancer, two of which are currently being tested in several ongoing clinical trials. Clay Siegall’s biotechnology firm has agreements with other companies such as Genencor International, Bristol-Myers Squibb, and Medarex. The company also holds licenses for its ADC technology with Eos Biotechnology, Genentech and Celltech Group.

Seattle Genetics was established in 1997 and has its headquarters located in Bothell, Washington. Among the founders of the firm is Clay B. Siegall, a renowned scientist in the field of biotechnology. Mr. Siegall serves as the president and Chief Executive Officer and is also the chair of the board. Dr. Siegall built Seattle Genetics on the basis of scientific advancement, drug development activities, thorough research and a passion for assisting patients. Through his hard work and devotion, Dr. Siegall has successfully guided the firm to its current leadership position in creating antibody-drug conjugates (ADCs) for treating cancer.

Dr. Clay B. Siegall’s reign as the president and CEO of Seattle Genetics has seen him develop an assortment of antibody-based cancer therapies such as ADCETRIS (brentuximab vedotin) which received quick approval by the FDA in 2011. He has also been on the front line in guiding Seattle Genetics’ capital funding activities, raising more than $675 million through private and public funding.

Mr. Siegall studied Bachelor of Science (B.S.), Zoology from the University of Maryland and holds a Doctor of Philosophy (Ph.D.) in Genetics from The George Washington University. Dr. Siegall has spent almost two decades understanding the science behind cancer and producing therapeutic drugs to treat several types of the ailment. Before co-founding Seattle Genetics, Mr. Siegall worked for Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997. From 1988 to 1991, Siegall worked for the National Cancer Institute, National Institutes of Health.
Mr. Siegall was appointed as a member of the Board of Directors of the biotechnology-based company, Mirna Therapeutics in January 2013. In his capacity, he would serve as an outside director. Mirna Therapeutics (Austin, Texas) was founded in 2007 and deals with microRNA in therapeutics.

Original Articles: